# Randomised trial of ifosfamide, carboplatin and etoposide with mid-cycle vincristine (VICE) versus standard practice chemotherapy in patients with limited small cell lung cancer (SCLC) and good performance status

Submission date	Recruitment status No longer recruiting	<ul><li>Prospectively registered</li></ul>		
06/04/2000		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
06/04/2000	Completed	[X] Results		
Last Edited	Condition category	[] Individual participant data		
02/09/2022	Cancer			

#### Plain English summary of protocol

https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/lu21-chemotherapy-for-small-cell-lung-cancer

# **Contact information**

# Type(s)

Scientific

#### Contact name

Dr Danielle Andrews

#### Contact details

MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA

### Additional identifiers

ClinicalTrials.gov (NCT) NCT00002822

#### Protocol serial number

**LU21** 

# Study information

#### Scientific Title

Randomised trial of ifosfamide, carboplatin and etoposide with mid-cycle vincristine (VICE) versus standard practice chemotherapy in patients with limited small cell lung cancer (SCLC) and good performance status

#### **Study objectives**

To compare an intensive regimen of VICE without dose reduction but with dose delay permitted versus standard practice chemotherapy in patients with limited stage SCLC and good performance status

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Not provided at time of registration

#### Study design

Randomised controlled trial

#### Primary study design

Interventional

#### Study type(s)

Treatment

# Health condition(s) or problem(s) studied

Cancer

#### Interventions

- 1. One group receives intensive regimen of VICE without dose reduction but with dose delay permitted
- 2. The other group receives standard practice chemotherapy

#### Intervention Type

Drug

#### **Phase**

**Not Specified** 

#### Drug/device/biological/vaccine name(s)

ifosfamide, carboplatin and etoposide with mid-cycle vincristine (VICE)

#### Primary outcome(s)

Survival time, quality of life

#### Key secondary outcome(s))

Not provided at time of registration

#### Completion date

01/12/2001

# **Eligibility**

#### Key inclusion criteria

- 1. Previously untreated SCLC
- 2. Limited disease
- 3. WHO 0-2
- 4. Normal blood count
- 5. Glomerular Filtration Rate (GFR) greater than 65 ml/min

#### Participant type(s)

**Patient** 

#### Healthy volunteers allowed

No

#### Age group

**Not Specified** 

#### Sex

**Not Specified** 

#### Total final enrolment

402

#### Key exclusion criteria

Not provided at time of registration

#### Date of first enrolment

01/12/1995

#### Date of final enrolment

01/12/2001

# Locations

#### Countries of recruitment

**United Kingdom** 

England

# Study participating centre MRC Clinical Trials Unit

London United Kingdom NW1 2DA

# Sponsor information

#### Organisation

Medical Research Council (MRC) (UK)

# Funder(s)

#### Funder type

Research council

#### **Funder Name**

Medical Research Council (MRC) (UK)

#### Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

#### **Funding Body Type**

Government organisation

#### **Funding Body Subtype**

National government

#### Location

**United Kingdom** 

# **Results and Publications**

#### Individual participant data (IPD) sharing plan

Not provided at time of registration

#### IPD sharing plan summary

Not provided at time of registration

#### **Study outputs**

Output type	<b>Details</b> results	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		20/11/2005		Yes	No
Plain English results			02/09/2022	No	Yes